Search

Your search keyword '"Gimenez-Arnau, Ana"' showing total 10 results
Start Over Author "Gimenez-Arnau, Ana" Topic angioedema
10 results on '"Gimenez-Arnau, Ana"'

2. Effects of pregnancy on chronic urticaria: Results of the PREG-CU UCARE study.

Author

Kocatürk E, Al-Ahmad M, Krause K, Gimenez-Arnau AM, Thomsen SF, Conlon N, Marsland A, Savk E, Criado RF, Danilycheva I, Fomina D, Godse K, Khoshkhui M, Gelincik A, Degirmentepe EN, Demir S, Ensina LF, Kasperska-Zajac A, Rudenko M, Valle S, Medina I, Bauer A, Zhao Z, Staubach P, Bouillet L, Küçük ÖS, Ateş C, and Maurer M

Subjects
Chronic Disease, Female, Gonadal Steroid Hormones, Humans, Pregnancy, Surveys and Questionnaires, Angioedema, Chronic Urticaria, Urticaria epidemiology
Abstract

Background: Chronic urticaria (CU) predominantly affects women, and sex hormones can modulate disease activity in female CU patients. As of now, the impact of pregnancy on CU is largely unknown., Aim: To analyze the course and features of CU during and after pregnancy., Patients and Methods: PREG-CU is an international, multicenter study of the Urticaria Centers of Reference and Excellence (UCARE) network. Data were collected via a 47-item questionnaire completed by CU patients, who became pregnant within the last 3 years., Results: A total of 288 pregnancies of 288 CU patients from 13 countries were analyzed (mean age at pregnancy: 32.1 ± 6.1 years, duration of CU: 84.9 ± 74.5 months; CSU 66.9%, CSU + CIndU 20.3%, CIndU 12.8%).During pregnancy, 51.1% of patients rated their CU as improved, 28.9% as worse, and 20.0% as unchanged.CU exacerbations most commonly occurred exclusively during the third trimester (in 34 of 124 patients; 27.6%) or the first (28 of 124; 22.8%). The risk factors for worsening of CU during pregnancy were having mild disease and no angioedema before pregnancy, not taking treatment before pregnancy, CIndU, CU worsening during a previous pregnancy, treatment during pregnancy, and stress as a driver of exacerbations. After giving birth, urticaria disease activity remained unchanged in 43.8% of CU patients, whereas 37.4% and 18.1% experienced worsening and improvement, respectively., Conclusions: These results demonstrate the complex impact of pregnancy on the course of CU and help to better counsel patients who want to become pregnant and to manage CU during pregnancy., (© 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2021
Full Text
View/download PDF

3. What lessons can we learn? Clinical and epidemiological retrospective analysis of 267 patients with urticaria in a Brazilian tertiary center.

Author

Criado RFJ, Criado PR, Baldavira N, Cardial D, Gimenez-Arnau AM, and Machado Filho CD

Subjects
Adult, Brazil epidemiology, Chronic Disease, Female, Humans, Retrospective Studies, Angioedema diagnosis, Angioedema epidemiology, Urticaria epidemiology
Abstract

Background: There are few epidemiological studies of urticaria, published in the indexed literature (PubMed/Medline)., Objective: The study aimed to evaluate the epidemiological and clinical data among patients with urticaria/angioedema attending a reference clinic in Brazil., Methods: Two hundred sixty-seven patients were evaluated retrospectively considering demographic data, time course of the disease, triggering symptoms, the presence of angioedema, complementary laboratory tests including total blood count, reactive-C protein, erythrocyte sedimentation rate, IgE serum levels, and other, as necessary., Results: The most commonly diagnosed type of urticaria was chronic spontaneous urticaria (56.93%). Angioedema was associated with chronic urticaria in 108 patients (40.08%)., Study Limitations: Unicentered and retrospective., Conclusion: Some relevant findings in this study are the observation of a female prevalence of cases (4-females: 1-man), a result more elevated than demonstrated in previous studies in Europe and Asia, the median age was 43-years old and the delay of time between the diagnosis of urticaria and the admission for treatment in a specialized center was approximately 2-years. Other multicenter studies can better establish these differences in Brazilian patients., (Copyright © 2021 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. All rights reserved.)

Published
2021
Full Text
View/download PDF

5. Occupational Contact Urticaria Syndrome

Author

Giménez-Arnau, Ana M., Pesqué, David, Maibach, Howard I., Berth-Jones, John, Series Editor, Goh, Chee Leok, Series Editor, Maibach, Howard I., Series Editor, and Giménez-Arnau, Ana M., editor

Published
2023
Full Text
View/download PDF

6. Biological drugs for the treatment of children with chronic spontaneous urticaria.

Author

Podder, Indrashis, Salman, Andaç, Asero, Riccardo, Teresa Caballero, Maria, Caffarelli, Carlo, De las Vecillas, Leticia, Gimenez-Arnau, Ana Maria, Giovannini, Mattia, Kocatürk, Emek, Kolkhir, Pavel, Manti, Sara, Navarro Cascales, Tatiana, and Maurer, Marcus

Subjects
ASTHMATICS, OFF-label use (Drugs), OMALIZUMAB, BRUTON tyrosine kinase, DUPILUMAB, URTICARIA
Abstract

Introduction: There is a significant prevalence of chronic spontaneous urticaria (CSU) in children across the globe. Some children with CSU do not achieve disease control with first-line antihistamine treatment and may need anti-IgE therapy with omalizumab. Recently, several novel treatment options, including dupilumab and BTK inhibitors, showed promising results in the treatment of antihistamine-refractory CSU in adults. However, information regarding their use in pediatric CSU is scarce, and most data is extrapolated from adult studies. Areas covered: The review highlights the evidence on the use of mAbs and small-molecule inhibitors in pediatric CSU and aims to bridge the knowledge gaps and highlight unmet needs. Expert opinion: Omalizumab is approved for allergic asthma patients aged ≥6 years, and some experience with omalizumab in children with CSU at this age has been published. However, approximately 5–10% of pediatric CSU patients may show insufficient response to omalizumab, necessitating other therapies. The available information on the off-label use of biologics other than omalizumab in children is limited to case reports. No data is available for other new therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Risk factors for systemic reactions in typical cold urticaria: Results from the COLD-CE study

Author

Emek Kocatürk, Ana Giménez-Arnau, Roberta Fachini Jardim Criado, David Pesqué, Maria Pasali, Solange Oliveira Rodrigues Valle, Simon Francis Thomsen, Mitja Košnik, Daria Fomina, Aliya Klyucharova, Célia Costa, Dejan Dinevski, Rongbiao Lu, Luis Felipe Ensina, Paraskevi Xepapadaki, Michael Makris, Sabine Altrichter, Maryam Khoshkhui, Naoko Inomata, Dalia Melina Ahsan, Elena Borzova, Maxi Brockstädt, Andrea Bauer, German D. Ramon, Xiaoyang Xue, Eduardo Magalhães de Souza Lima, Zuotao Zhao, Kanokvalai Kulthanan, Dorothea Terhorst-Molawi, Jesper Grønlund Holm, Mona Al-Ahmad, Jovan Miljković, Marisa Paulino, Margarida Gonçalo, Semra Demir, Alicja Kasperska-Zajac, Agnieszka Sikora, Jonny Peter, M. Gotua, Natalya Maltseva, Michael Rudenko, Marcus Maurer, Mojca Bizjak, Carla Ritchie, Aslı Gelincik, Raisa Meshkova, Nicola Wagner, Publica, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Bizjak, Mojca, Kosnik, Mitja, Dinevski, Dejan, Thomsen, Simon Francis, Fomina, Daria, Borzova, Elena, Kulthanan, Kanokvalai, Meshkova, Raisa, Ahsan, Dalia Melina, Al-Ahmad, Mona, Altrichter, Sabine, Bauer, Andrea, Brockstadt, Maxi, Costa, Celia, Demir, Semra, Criado, Roberta Fachini, Ensina, Luis Felipe, Gelincik, Aslı, Gimenez-Arnau, Ana Maria, Goncalo, Margarida, Gotua, Maia, Holm, Jesper Gronlund, Inomata, Naoko, Kasperska-Zajac, Alicja, Khoshkhui, Maryam, Klyucharova, Aliya, Lu, Rongbiao, Makris, Michael, Maltseva, Natalya, Miljkovic, Jovan, Pasali, Maria, Paulino, Marisa, Pesque, David, Peter, Jonny, Ramon, German Dario, Ritchie, Carla, Valle, Solange Oliveira Rodrigues, Rudenko, Michael, Sikora, Agnieszka, Lima, Eduardo M. Souza, Wagner, Nicola, Xepapadaki, Paraskevi, Xue, Xiaoyang, Zhao, Zuotao, Terhorst-Molawi, Dorothea, Maurer, Marcus, and School of Medicine

Subjects
medicine.medical_specialty, Urticaria, adrenaline autoinjector, Immunology, systemic reactions, Cold urticaria, Autoinjector, Risk Factors, medicine, risk factors, Immunology and Allergy, Animals, Humans, Chronic Urticaria, Angioedema, Adrenaline autoinjector, COLD-CE, Risk factors, Systemic reactions, Allergy, business.industry, Pruritus, Cold air, Insect Bites and Stings, medicine.disease, Dermatology, Hymenoptera, cold urticaria, Cold Temperature, Sting, Systemic reaction, Cross-Sectional Studies, Concomitant, medicine.symptom, business, Anaphylaxis, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
Abstract

Background: cold urticaria (ColdU), that is, the occurrence of wheals or angioedema in response to cold exposure, is classified into typical and atypical forms. The diagnosis of typical ColdU relies on whealing in response to local cold stimulation testing (CST). It can also manifest with cold-induced anaphylaxis (ColdA). We aimed to determine risk factors for ColdA in typical ColdU. Methods: an international, cross-sectional study COLD-CE was carried out at 32 urticaria centers of reference and excellence (UCAREs). Detailed history was taken and CST with an ice cube and/or TempTest(R) performed. ColdA was defined as an acute cold-induced involvement of the skin and/or visible mucosal tissue and at least one of: cardiovascular manifestations, difficulty breathing, or gastrointestinal symptoms. Results: of 551 ColdU patients, 75% (n = 412) had a positive CST and ColdA occurred in 37% (n = 151) of the latter. Cold-induced generalized wheals, angioedema, acral swelling, oropharyngeal/laryngeal symptoms, and itch of earlobes were identified as signs/symptoms of severe disease. ColdA was most commonly provoked by complete cold water immersion and ColdA caused by cold air was more common in countries with a warmer climate. Ten percent (n = 40) of typical ColdU patients had a concomitant chronic spontaneous urticaria (CSU). They had a lower frequency of ColdA than those without CSU (4% vs. 39%, p = .003). We identified the following risk factors for cardiovascular manifestations: previous systemic reaction to a Hymenoptera sting, angioedema, oropharyngeal/laryngeal symptoms, and itchy earlobes. Conclusion: coldA is common in typical ColdU. High-risk patients require education about their condition and how to use an adrenaline autoinjector., GA(2)LEN UCARE Network

Published
2021
Full Text
View/download PDF

9. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

Author

Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Zuberbier, Torsten, Abdul Latiff, Amir Hamzah, Abuzakouk, Mohamed, Aquilina, Susan, Asero, Riccardo, Baker, Diane, Ballmer-Weber, Barbara, Bangert, Christine, Ben-Shoshan, Moshe, Bernstein, Jonathan A., Bindslev-Jensen, Carsten, Brockow, Knut, Brzoza, Zenon, Chong Neto, Herberto Jose, Church, Martin K., Criado, Paulo R., Danilycheva, Inna V., Dressler, Corinna, Ensina, Luis Felipe, Fonacier, Luz, Gaskins, Matthew, Gaspar, Krisztian, Gelincik, Asli, Gimenez-Arnau, Ana, Godse, Kiran, Goncalo, Margarida, Grattan, Clive, Grosber, Martine, Hamelmann, Eckard, Hebert, Jacques, Hide, Michihiro, Kaplan, Allen, Kapp, Alexander, Kessel, Aharon, Kulthanan, Kanokvalai, Larenas-Linnemann, Desiree, Lauerma, Antti, Leslie, Tabi A., Magerl, Markus, Makris, Michael, Meshkova, Raisa Y., Metz, Martin, Micallef, Daniel, Mortz, Charlotte G., Nast, Alexander, Oude-Elberink, Hanneke, Pawankar, Ruby, Pigatto, Paolo D., Ratti Sisa, Hector, Rojo Gutierrez, Maria Isabel, Saini, Sarbjit S., Schmid-Grendelmeier, Peter, Sekerel, Bulent E., Siebenhaar, Frank, Siiskonen, Hanna, Soria, Angele, Staubach-Renz, Petra, Stingeni, Luca, Sussman, Gordon, Szegedi, Andrea, Thomsen, Simon Francis, Vadasz, Zahava, Vestergaard, Christian, Wedi, Bettina, Zhao, Zuotao, Maurer, Marcus, and School of Medicine

Subjects
Angioedema, Consensus, Evidence-based, Hives, Itch, Mast cell, Urticaria, Wheal, Allergy, Immunology
Abstract

This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA(2)LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria., Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs); European Union (EU); 6th Framework Programme; Global Allergy and Asthma European Network (GA2LEN); European Academy of Allergology and Clinical Immunology (EAACI); Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI); European Dermatology Forum (EDF)

Published
2021

10. Definition, aims, and implementation of GA [sup] 2 LEN/HAEi Angioedema Centers of Reference and Excellence

Author

Kemal Özyurt, Teresa Caballero, Aharon Kessel, Andrew J. MacGinnitie, Solange Oliveira Rodrigues Valle, Anthony J. Castaldo, Markus Magerl, Regis A. Campos, Adam Reich, Heike Röckmann-Helmbach, R. Y. Meshkova, Mario Sánchez-Borges, Richard G. Gower, Anna Zalewska-Janowska, Daria Fomina, Célia Costa, Allen P. Kaplan, Marc A. Riedl, Naoko Inomata, Avner Reshef, Alejandro Malbrán, Aurélie Du-Thanh, N. Prior, Hilary Longhurst, Margarida Gonçalo, Kiran Godse, Rosana Câmara Agondi, Andreas Kleinheinz, Inmaculada Martinez-Saguer, Mona Al-Ahmad, Thilo Jakob, Luis Felipe Ensina, José Ignacio Larco Sousa, Anna Tagka, Chikako Nishigori, Nicola Wagner, Hye Ryun Kang, Michael Makris, Nicholas Brodszki, Ricardo Dario Zwiener, Jan Nicolay, Alicja Kasperska-Zając, Iris V Medina, Ignacio J. Ansotegui, Marcin Stobiecki, Alejandro Berardi, Danny M. Cohn, Claudio A S Parisi, Angèle Soria, Torsten Zuberbier, Dario O. Josviack, E Serra-Baldrich, Jonathan A. Bernstein, Anette Bygum, Isao Ohsawa, Henriette Farkas, Iman Nasr, Thomas Buttgereit, Jonathan Peter, Carsten Bindslev-Jensen, Paulo Ricardo Criado, Wolfgang Pfützner, Natalia Fili, Silvia Mariel Ferrucci, Petra Staubach, Peter Schmid-Grendelmeier, M. Gotua, Marcus Maurer, Jose Fabiani, Gordon Sussman, A. Marsland, Konrad Bork, Andrea Zanichelli, Simon Francis Thomsen, Isabelle Boccon-Gibod, Mauro Cancian, German D. Ramon, Zuotao Zhao, Nikolaos G. Papadopoulos, Martijn B. A. van Doorn, Andrea Bauer, Kanokvalai Kulthanan, Claudio Fantini, Henrik Balle Boysen, Lilian Varga, Dorota Krasowska, Ana Giménez-Arnau, Werner Aberer, Ivan Cherrez-Ojeda, Roberta F. Criado, Constance H. Katelaris, Martin Metz, Riccardo Asero, Mitja Košnik, Stephen Betschel, M Sendhil Kumaran, Sigurd Broesby-Olsen, Moshe Ben-Shoshan, Rand Arnaout, Regina Treudler, Laurence Bouillet, Natalia Ilina, Maryam Ali Al-Nesf, Emek Kocatürk, Emel Aygören-Pürsün, William R. Lumry, Guillermo Guidos-Fogelbach, Yuxiang Zhi, Mark Gompels, Andac Salman, Christina Weber-Chrysochoou, Michihiro Hide, Young Min Ye, Aslı Gelincik, William B Smith, Timothy J. Craig, Bruce Ritchie, Daniel O. Vázquez, Mojca Bizjak, Atsushi Fukunaga, Ragıp Ertaş, Urs C. Steiner, Faradiba Sarquis Serpa, Farrukh R. Sheikh, Michael Rudenko, Paula J. Busse, Luisa Karla de Paula Arruda, Liangchun Wang, Todor A. Popov, Anete Sevciovic Grumach, Joachim Dissemond, Dorottya Csuka, Ignasi Figueras-Nart, Aleena Banerji, Tıp Fakültesi, Kemal Özyurt / 0000-0002-6913-8310, Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, Dermatology, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Maurer, Marcus, Werner, Aberer, Agondi, Rosana, Al-Ahmad, Mona, Al-Nesf, Maryam Ali, Ansotegui, Ignacio, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Aygoeren-Puersue, Emel, Banerji, Aleena, Bauer, Andrea, Ben-Shoshan, Moshe, Berardi, Alejandro, Bernstein, Jonathan A, Betschel, Stephen, Bindslev-Jensen, Carsten, Bizjak, Mojca, Boccon-Gibod, Isabelle, Bork, Konrad, Bouillet, Laurence, Boysen, Henrik Balle, Brodszki, Nicholas, Broesby-Olsen, Sigurd, Busse, Paula, Buttgereit, Thomas, Bygum, Anette, Caballero, Teresa, Campos, Regis A., Cancian, Mauro, Cherrez-Ojeda, Ivan, Cohn, Danny M., Costa, Celia, Craig, Timothy, Criado, Paulo Ricardo, Criado, Roberta F., Csuka, Dorottya, Dissemond, Joachim, Du-Thanh, Aurelie, Ensina, Luis Felipe, Ertaş, Ragıp, Fabiani, Jose E., Fantini, Claudio, Farkas, Henriette, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fili, Natalia L., Fomina, Daria, Fukunaga, Atsushi, Gelincik, Aslı, Gimenez-Arnau, Ana, Godse, Kiran, Gompels, Mark, Goncalo, Margarida, Gotua, Maia, Gower, Richard, Grumach, Anete S, Guidos-Fogelbach, Guillermo, Hide, Michihiro, Ilina, Natalia, Inomata, Naoko, Jakob, Thilo, Josviack, Dario O., Kang, Hye-Ryun, Kaplan, Allen, Kasperska-Zajac, Alicja, Katelaris, Constance, Kessel, Aharon, Kleinheinz, Andreas, Kosnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Larco Sousa, Jose Ignacio, Longhurst, Hilary J., Lumry, William, MacGinnitie, Andrew, Magerl, Markus, Makris, Michael P., Malbran, Alejandro, Marsland, Alexander, Martinez-Saguer, Inmaculada, Medina, Iris V., Meshkova, Raisa, Metz, Martin, Nasr, Iman, Nicolay, Jan, Nishigori, Chikako V., Nishigori, Chikako, Ohsawa, Isao, Özyurt, Kemal, Papadopoulos, Nikolaos G., Parisi, Claudio A. S., Peter, Jonathan Grant, Pfuetzner, Wolfgang, Popov, Todor, Prior, Nieves, Ramon, German D., Reich, Adam, Reshef, Avner, Riedl, Marc A., Ritchie, Bruce, Rockmann-Helmbach, Heike, Rudenko, Michael, Salman, Andaç, Sanchez-Borges, Mario, Schmid-Grendelmeier, Peter, Serpa, Faradiba S., Serra-Baldrich, Esther, Sheikh, Farrukh R., Smith, William, Soria, Angele, Staubach, Petra, Steiner, Urs C., Stobiecki, Marcin, Sussman, Gordon, Tagka, Anna, Thomsen, Simon Francis, Treudler, Regina, Valle, Solange, van Doorn, Martijn, Varga, Lilian, Vazquez, Daniel O., Wagner, Nicola, Wang, Liangchun, Weber-Chrysochoou, Christina, Ye, Young-Min, Zalewska-Janowska, Anna, Zanichelli, Andrea, Zhao, Zuotao, Zhi, Yuxiang, Zuberbier, Torsten, Zwiener, Ricardo D., Castaldo, Anthony, and School of Medicine

Subjects
medicine.medical_specialty, Edema angioneuròtic, Urticaria, media_common.quotation_subject, Immunology, education, GA2LEN, Angioedema, Center, Excellence, Management, urticaria, centres of reference and excelence, immune system diseases, center, medicine, Immunology and Allergy, Center (algebra and category theory), Angioneurotic edema, skin and connective tissue diseases, media_common, udc:616.1, business.industry, angioedema, humanities, referenčni centri odličnosti, Medicine, Allergy, Family medicine, excellence, medicine.symptom, business, Global Allergy and Asthma European Network, Urticària, management
Abstract

This document summarizes the aims of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence (ACAREs) and elaborates the requirements that ACAREs must fulfill to become certified. It also provides (see Appendix S1) background information on GA2LEN and HAEi, including HAEi member organizations and regional patient advocates, on why we need an Angioedema Center of Reference and Excellence (ACARE) program and network, and on the accreditation and certification process, governance and funding, and on the interaction with other GA2LEN networks of centers of reference and excellence. The protocols, aims, requirements, and provisions related to becoming a certified CARE are based on (a) the experience of the GA2LEN UCARE network and (b) input from angioedema patients, general practitioners, and angioedema specialists.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results